SG11201811227QA - Method for facilitating maturation of the mammalian immune system - Google Patents

Method for facilitating maturation of the mammalian immune system

Info

Publication number
SG11201811227QA
SG11201811227QA SG11201811227QA SG11201811227QA SG11201811227QA SG 11201811227Q A SG11201811227Q A SG 11201811227QA SG 11201811227Q A SG11201811227Q A SG 11201811227QA SG 11201811227Q A SG11201811227Q A SG 11201811227QA SG 11201811227Q A SG11201811227Q A SG 11201811227QA
Authority
SG
Singapore
Prior art keywords
international
davis
rule
california
street
Prior art date
Application number
SG11201811227QA
Inventor
David Kyle
Steven Frese
Samara Freeman-Sharkey
Bethany Henrick
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of SG11201811227QA publication Critical patent/SG11201811227QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pediatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

0 Q o ,0 Q 0 10 20 30 40 Sampling Day FIG. 1 60 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) WIP0 I PCT onion OH oI0IIIIIIII1101VIII 111110 Hs (10) International Publication Number WO 2018/006080 Al (51) International Patent Classification: A23L 33/135 (2016.01) A61K 35/741 (2015.01) A61K 31/702 (2006.01) A61K 35/745 (2015.01) (21) International Application Number: PCT/US2017/040530 (22) International Filing Date: 30 June 2017 (30.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/357,820 01 July 2016 (01.07.2016) US 62/397,788 21 September 2016 (21.09.2016) US (71) Applicant: EVOLVE BIOSYSTEMS INC. [US/US]; 2121 2nd Street, Suite B107, Davis, California 95618 (US). (72) Inventors: KYLE, David; P.O. Box 119, Gualala, Califor- nia 95445 (US). FRESE, Steven; 9163 Olmos Lane, Davis, California 95616 (US). FREEMAN-SHARKEY, Samara; 5248 Hamel Street, Davis, California 95618 (US). HEN- RICK, Bethany; 521 7th Street, Cottage 10, Davis, Cali- fornia 95616 (US). (74) Agent: POSORSKE, Laurence H. et al.; Hunton & Williams LLP, Intellectual Property Department, 2200 Pennsylvania Ave., NW, Washington, District of Columbia 20037 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: METHOD FOR FACILITATING MATURATION OF THE MAMMALIAN IMMUNE SYSTEM (57) : The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. *t These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a 1-1 © source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal. O [Continued on next page] WO 2018/006080 Al MIDEDIMOMMIDIRER 10101 1101 INIIMMOIHMEMOIS UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(1)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201811227QA 2016-07-01 2017-06-30 Method for facilitating maturation of the mammalian immune system SG11201811227QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357820P 2016-07-01 2016-07-01
US201662397788P 2016-09-21 2016-09-21
PCT/US2017/040530 WO2018006080A1 (en) 2016-07-01 2017-06-30 Method for facilitating maturation of the mammalian immune system

Publications (1)

Publication Number Publication Date
SG11201811227QA true SG11201811227QA (en) 2019-01-30

Family

ID=60785488

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811227QA SG11201811227QA (en) 2016-07-01 2017-06-30 Method for facilitating maturation of the mammalian immune system

Country Status (9)

Country Link
US (2) US11318175B2 (en)
EP (1) EP3478093A4 (en)
CN (2) CN109475169A (en)
AU (2) AU2017290900A1 (en)
BR (1) BR112018076927A2 (en)
CA (1) CA3029631A1 (en)
MX (2) MX2018015725A (en)
SG (1) SG11201811227QA (en)
WO (1) WO2018006080A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013016606A2 (en) 2010-12-31 2016-09-27 Abbott Lab processes for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ES2657744T3 (en) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosaccharides to prevent injuries and / or promote healing of the gastrointestinal tract
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
KR20190045228A (en) * 2016-08-31 2019-05-02 올리고사이언스 바이오테크놀로지 게엠베하 Uses of human milk oligosaccharides in calf fattening
EP3672600A4 (en) 2017-08-21 2021-05-19 Glycom A/S Synthetic composition for reducing allergy symptoms
EP3681521A4 (en) * 2017-09-13 2021-05-19 Evolve Biosystems Inc. Metabolomic revision of mammalian infants
CN112135520B (en) * 2018-01-03 2024-03-29 英凡特健康有限公司 Method for determining dysbiosis in intestinal microbiome
WO2019143871A1 (en) * 2018-01-17 2019-07-25 Evolve Biosystems, Inc. Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains
US11554131B2 (en) 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
GB201900754D0 (en) 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
GB201900744D0 (en) 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
GB201900745D0 (en) 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
GB201900750D0 (en) 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
GB201914385D0 (en) 2019-10-04 2019-11-20 Mars Inc Microbiome Interventions
CN112870233B (en) * 2019-11-29 2024-08-23 伊利伊诺科技(上海)有限责任公司 Composition containing bifidobacterium lactis and breast milk oligosaccharide and application thereof
CA3179561A1 (en) * 2020-04-08 2021-10-14 Megmilk Snow Brand Co., Ltd. Composition for improving gut microbiota
BG67567B1 (en) * 2020-05-27 2023-09-15 Гама Консулт-Калинкин, Прокопов И С-Ие Сд Quantitative assessment method for rapid prediction and control of dysbiosis in breast-fed newborns aged one month to one year
US20240122999A1 (en) * 2021-02-22 2024-04-18 Tate & Lyle Solutions Usa Llc Methods and Compositions Using Combinations of Lactobacillus Mucosae and Soluble Dietary Fiber
EP4094590A1 (en) * 2021-05-27 2022-11-30 Tate & Lyle Solutions USA LLC Methods and compositions using combinations of lactobacillus mucosae and soluble dietary fiber
GB2628547A (en) 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
PL1920781T3 (en) 2006-11-10 2015-06-30 Glycotope Gmbh Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
JP2012520325A (en) * 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Prebiotic oligosaccharide
US20110066700A1 (en) 2009-09-15 2011-03-17 Jackson Chao Behavior monitoring system
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
SG10201707519PA (en) * 2010-12-31 2017-10-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
CN103763940B (en) * 2010-12-31 2015-10-14 雅培制药有限公司 Promote the probio of effective microorganisms growth and the conjunction benefit element combination of human milk oligosaccharides
CN104507483A (en) * 2012-04-13 2015-04-08 波士顿学院理事会 Prebiotic compositions and methods of use
EP2951283A4 (en) * 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2965663C (en) 2014-10-24 2023-04-04 Evolve Biosystems, Inc. Activated bifidobacteria and methods of use thereof
MY186733A (en) 2014-10-29 2021-08-15 Biogaia Ab Use of l. reuteri for recovery of microbiota dysbiosis in early life
EP3229595B1 (en) 2014-12-12 2021-02-03 The Regents of the University of California Reduction of milk glycans and their degradation products in the neonate gut
WO2016105513A1 (en) 2014-12-23 2016-06-30 Evolve Biosystems Inc. Method for the noninvasive detection of activated bifidobacteria
CA2979086A1 (en) * 2015-03-12 2016-09-15 The University Of British Columbia Bacterial compositions and methods of use thereof
US20190216861A1 (en) * 2015-09-22 2019-07-18 Mayo Foundation For Medical Education And Research Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
CN105166914A (en) 2015-10-27 2015-12-23 江西美庐乳业集团有限公司 Nutrition bag capable of regulating intestinal micro-ecological environment, promoting baby disease resistance and improving diarrhea
CN108348536B (en) 2015-11-17 2021-09-24 格礼卡姆股份公司 Synthetic compositions for treating antibiotic-associated complications

Also Published As

Publication number Publication date
WO2018006080A1 (en) 2018-01-04
EP3478093A1 (en) 2019-05-08
US20190224254A1 (en) 2019-07-25
US11318175B2 (en) 2022-05-03
AU2023204422A1 (en) 2023-08-03
MX2018015725A (en) 2019-09-09
MX2022009575A (en) 2022-09-09
US20220313759A1 (en) 2022-10-06
EP3478093A4 (en) 2020-03-04
BR112018076927A2 (en) 2019-04-02
CA3029631A1 (en) 2018-01-04
CN109475169A (en) 2019-03-15
CN117385064A (en) 2024-01-12
AU2017290900A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
SG11201811227QA (en) Method for facilitating maturation of the mammalian immune system
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201805186VA (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201807912SA (en) Vaccine against rsv
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201809593YA (en) Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11202000263QA (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
SG11201804996TA (en) Food and beverage products comprising low calorie, low glycemic index (gi), and sustained energy release sugar composition
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201810470XA (en) Lysine conjugated immunoglobulins
SG11201805771XA (en) Systems and methods for preparation of platelets
SG11201805001UA (en) Method of treating influenza a
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia